June 3rd, 2014
Prophylactic ICDs Appear Effective in Less Severe HF Patients
Larry Husten, PHD
Implantable cardioverter-defibrillators are routinely implanted in heart failure patients with ejection fractions of 35% and lower to prevent sudden cardiac death. However, the benefits in patients at the higher end of the spectrum — EFs between 30% and 35% — have not been well demonstrated in clinical trials, since few patients in this range have […]
May 8th, 2014
Selections from Richard Lehman’s Literature Review: May 8th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include darapladib for preventing ischemic events in stable CHD, the DAMASCENE analysis, a review of John Brush’s new book, and more.
April 9th, 2014
TOPCAT Fails to Find Advantage for Spironolactone in HFPEF
Larry Husten, PHD
Although a significant portion of people with heart failure have preserved ejection fraction, none of the proven heart failure therapies has been shown to be beneficial in this important and growing heart failure subpopulation. Now a new NHLBI-funded study has failed to find a benefit in this group for spironolactone, which is a cornerstone of […]
February 4th, 2013
Selections from Richard Lehman’s Literature Review: February 4th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include blood transfusion and increased mortality in MI, proteotoxicity and cardiac dysfunction in the elderly, combined fitness and statin treatment on mortality in veterans with dyslipidemia, and more.
December 3rd, 2012
Selections from Richard Lehman’s Literature Review: December 3rd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and more.